WO2005113537B1 - Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions - Google Patents
Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditionsInfo
- Publication number
- WO2005113537B1 WO2005113537B1 PCT/US2005/016525 US2005016525W WO2005113537B1 WO 2005113537 B1 WO2005113537 B1 WO 2005113537B1 US 2005016525 W US2005016525 W US 2005016525W WO 2005113537 B1 WO2005113537 B1 WO 2005113537B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituted
- alkyl
- occurrence
- carbon atoms
- heterocycle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Abstract
The present invention provides novel ureas containing N-aryl or N-heteroaryl substituted heterocycles and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y1 receptor activity.
Claims
[Received by the International Bureau on December 22, 2005 (22/12/2005); original claims 1, 10 and 11 have been amended. Other claims remain unchanged]
1. A compound of Formula (I):
(D or a stereoisomer or pharmaceutically acceptable salt, or solvate thereof, wherein: ring A is Cδ-io aryl substituted with 0-5 R1 , or a 5- to 10-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NR1 *, O, and S(O)p, wherein said heterocycle is substituted with 0-5 R1; ring B is phenyl or naphthyl substituted with 0-4 R?, or a 5- to 10-membered heteroaryl comprising: carbon atoms and 1-4 ring heteroatoms selected from N, NR11, S(O )p, and O, wherein said heteroaryl is substituted with 0-4 R7; ring D is substituted with 0-5 R6a and selected from:
wherein D1 is a 5- to 7-raembered carbocycle or a 5-6-membered heterocycle comprising: carbon atoms and 0-3 ring heteroatoms selected from N, NR1 ] , O, and S(O)p, and 0-2 carbonyl groups, and 0-3 double bonds;
W is O or S; X2 is -(CRJ 6Rl 7)s_5 or _(CR16R17)tC(O)(CR] ^Rl 7)r;
R1 is, independently at each occurrence, H, =0, F, Cl, Br, I5 CF3, -CF2CF3, OCF3, -OCF2CF2H, -OCF2CF3, SiMe3, -(CRfRf)rORc, SRC, CN5 NO2, -(CRfRf)rNR12R13, -(CRfRfJr-C(O)R0, -(CRfRf)r-C02Rc, -(CRfRf)rC(O)NR12R13, -C(O)NR14(CRfRf)tN12R135 -(CRfRf)rOC(O)NR12R13, -(CRfRf)1-NR14C(O)NR12R13, -(CRfRf)rNR14C(0)Rd, -(CRfRf)rNR14C(O)ORh, -NR14(CRfRf)nC(0)Rd, -NR14CO(CRfRf)nORc, -(CH2V-CR13O=NOR0), -S(O)pNR12R13, -(CRfRf)rNR14S(O)pNR12R13, -NR14SO2CF3, -NR14S(0)pRd -S(O)2CF3, -S(O)Rd, -S(O)2Rd, -OP(O)(OEt)2, -O(CH2)2OP(O)(OEt)2; 4,4,5,5-tetramethyl-l,3,2-dioxabprolarryl, C1-8 alkyl substituted with 0-2 Ra, C2-S alkenyl substituted with 0-2 Ra, C2_8 alkynyl substituted with 0-2 Ra,
-(CRfRf)r-C3.i3 carbocycle substituted with 0-5 Rb, or -(CRfRf)r-5- to 10-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NR11, O, and S(O)p, wherein said heterocycle is substituted with 0-5 Rb; alternatively, two R1S on two adjacent carbon atoms are combined with the carbon atoms to which they are attached, form a 5- to 10-membered carbocycle or heterocycle comprising: carbon atoms and 0-3 additional heteroatoms selected from N, NR1 1 J O, and S(O)p, and 0-2 carbonyl groups, wherein said carbocycle or heterocycle is substituted with 0-4 Rb;
R6a is, independently at each occurrence, =0, F5 Cl, Br, I, -(CR1R1VOR0, SR0, CN, NO2, CF3, OCF3, -CF2CF3, -OCF2CF2H, -OCF2CF3, -(CRfRf)rNR12R13, -C(O)R0, -(CRfRf)r-C(O)OR°, -(CRfRf)1-C(O)NR12R13, -(CRfRf)rNR14C(O)Rd, -S(O)pNR12R13, -S(O)Rd, -S(O)2Rd, Si(Me)3, Si(Ci_4 alkyl)3, Cμ4 haloalkyl, Ci_4 haloalkyloxy-, C1-4 alkyloxy-, C1^ alkylthio-, Ci-C4 alkyl-C(O)-, Ci_4 alkyl-O-C(O)-, C]_4 allcyl-C(O)NH-, Cμ8 alkyl substituted with 0-1 Ra,
C2-8 alkenyl substituted with 0-1 Ra, C2-8 alkynyl substituted with 0-1 Ra,
carbocycle substituted with 0-2 Re, or -(CRfRf)r-5- to 10-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NR1 *, O5 and S(O)p, wherein said heterocycle is substituted with 0-2 Re; alternatively, when two R^a groups are attached to the same carbon atom or silicon atom, together with the carbon atom or silicon atom to which they are attached, they form a 3- to 7-membered carbocyclic or heterocyclic ring comprising: carbon atoms and 0-3 heteroatoms selected from N5 NR11, O, Si, and S(O)p, 0-1 carbonyl and 0-3 ring double bonds, wherein said carbocyclic or heterocyclic ring is substituted with 0-3 Rb; alternatively, when two R6a groups are attached to adjacent atoms, together with the atoms to which they are attached they form a 5- to 7-membered carbocyclic or heterocyclic ring comprising: carbon atoms and 0-2 heteroatoms selected from N, NR11, O, Si, and S(O)p, 0-1 carbonyl and 0-3 ring double bonds, wherein said carbocyclic or heterocyclic ring is substituted with 0-3 Rb;
R7 is, independently at each occurrence, H, =0, F, Cl, Br, I5 OCF3, CF3, ORC, - SRC, CN, NO2, -NR12R13, _c(0)Rc, -C(O)ORC, -C(O)NR12R13, -NR14C(0)Rd, -S(O)pNR12R13, -S(O)Rd, -S(O)2Rd, C1 -8 alkyl substituted with 0-2 Ra, C2-S alkenyl substituted with 0-2 Ra, C2-S alkynyl substituted with 0-2 Ra, -(CRfRf)r-C3_io carbocycle substituted with 0-3 Rb, or -(CRfRf)r-5- to 10-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NR7b, O5 and S(O)p, wherein said heterocycle is substituted with 0-3 Rb; alternatively, two R7S on two adjacent carbon atoms form a 5- to 7-membered carboc3'clic or heterocyclic ring comprising: carbon atoms and 0-3 ring heteroatoms selected from O, N5 NR7b, and S(O)p, wherein said carbocyclic or heterocyclic ring is substituted with 0-2 R7c;
R7b is H, C14 alkyl, -C(O)(Ci_4 alkyl), -C(O)phenyl, -C(O)benzyl, or benzyl; R7c is, independently at each occurrence, H, F, Cl, Br5 15 OCF3, CF3, ORC, SRc, CN, NO2, -NR12R13, -C(O)R0, -C(O)ORc, -C(O)NR12R13, -NR^C(O)Rd
-S(COpNR12R13, -S(O)Rd, -S(O)2Rd, C]_4 ^i phenyl substituted with 0-3 Rb, or benzyl substituted with 0-3 Rb;
R11 is, independently at each occurrence, H, Cj-4 alkoxy, Cj.g alkyl substituted with 0-2 Ra, C2-4 alkenyl substituted with 0-1 Ra, C2-4 alkynyl substituted with 0- 1 Ra, -C(O)(C i^ alkyl), -C(O)(CH2)n(C3_6 cycloalkyl),
-C(0)(CH2)Π(C6-JO aryl), -C(O)(CH2)n(5- to 10-membered heteroaryl), -C(O)O(CL8 alkyl), -C(O)O(CH2)n(C3_6 cycloalkyl), -C(0)0(CH2)n(C6.io aryl), -C(O)O(CH2)n(5- to 10-memberedheteroaryl), -C(O)O(CH2)2_4(Ci_4 alkyl), -C(O)NH(C i_8 alkyl), -C(O)NH(CH2)n(C3-6 cycloalkyl), -C(0)NH(CH2)n(C6-io aryl), -C(O)NH(CH2)n(5- to 10-membered lieteroaryl), -S(O)2(CL8 alkyl), -S(O)2(CH2)n(C3-6 cycloalkyl), -S(O)2(CH2)n(C6_10 aryl), -S(O)2(CH2)n(5- to 10-membered heteroaryl), -(CRfRf)rC3.io carbocycle, or -(CRfRf)r-5- to 10-membered heterocycle; wherein said alkyl, cycloalkyl, phenyl, aryl, and carbocycle are substituted with 0-2 R^, and said heteroaryl and heterocycle are substituted with 0-2 Rb and comprise: carbon atoms and 1-4 heteroatoms selected from N, NRf, O, and S(O)p;
R12 is, independently at each occurrence, H5 CL6 alkyl, -C(O)(Ci_6 alkyl), -C(0)(CH2)n(C6-io aryl), -C(O)(CH2)n(5- to 10-membered heteroaryl), -C(O)O(CL4 alkyl), -C(O)OCH2(C6-I0 aryl), -(CH2)nC(O)OCH2(5- to 10-membered heteroaryl), -(CH2)nOC(0)(Ci .4 alkyl), -(CH2)nOC(0)(C6-io aryl), -(CH2)nOC(O)(5- to 10-membered heteroaryl), -(CH2)nC(O)O(CL4 alkyl), -(CH2)nC(O)O(C6-] 0 aryl), -(CH2)nC(O)O(5- to 10-membered heteroaryl), -(CH2)nC(O)NH(Ci_6 alkyl), -(CH2)aC(0)NH(C6-io aryl), -(CH2)nC(O)NH(5- to 10-membered heteroaryl), -(CH2)tOC(O)NH(Ci.6 alkyl), -(CH2)tOC(0)NH(C6_io aryl),
-(CH2)tOC(O)NH(5- to 10-membered heteroaryl), -S(O)2(CL6 alkyl), -S(0)2(CH2)n(C6-io aryl), -S(O)2(CH2)n(5- to 10-membered heteroaryl),
aryl), or -(CRfRf)n- 5- to 10-membered heteroaryl; wherein said alkyl, and aryl are substituted with 0-2 RS; and said heteroaryl is substituted with 0-2
RS and comprises: carbon atoms and 1-4 heteroatoms selected from N, NR1 !, O, and S(0)p;
R13 is, independently at each occurrence, H, Cμg alkyl, or -(CH2)n-pb-enyl; alternatively, R12 and R13, when attached to the same nitrogen, combine to form a 5- to 10-membered heterocyclic ring comprising: carbon atoms and 1-2 additional heteroatoms selected from N, NR11, O, and S(O )p;
R14 is, independently at each occurrence, H, C\.β alkyl substituted with 0-2 R14a, C2-6 alkenyl substituted with 0-2 R14a, C2-6 alkynyl substituted with 0-2 R14a, -(CH2)r-C34o carbocycle substituted with 0-3 RS, or -(CH2)r-5- to 10-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NR11, O, and S(O)p, wherein said heterocycle is substituted with 0-3 RS;
R14a is, independently at each occurrence, H, Ci_4 alkyl, ORf, Cl, F, Br, I, =0, CF3, CN5 NO2, -C(O)Rf -C(O)ORf, -C(O)NR12R13, or -S(O)pRf;
R16 is, independently at each occurrence, H, F5 Cj_6 alkyl substituted with 0-2 Ra, C2-6 alkenyl substituted with 0-2 Ra, C2-6 alkynyl substituted with. 0-2 Ra, or -(CH2)r-phenyl substituted with 0-2 Rb;
R17 is, independently at each occurrence, H, OH, Cμg alkyl, or -(CH2)n-plienyl; alternatively, R16 and R17 on the same carbon atom combine to form a 3- to 7-membered carbocyclic or heterocyclic ring comprising: carbon atoms and 0-2 heteroatoms selected from N, NR11, O, and S(O)p, 0-1 carbonyl, and 0-3 double bonds, wherein said carbocyclic or heterocyclic ring is substituted with 0-2 Rb; alternatively, two R16 groups on adjacent atoms combine to form a 3- to 7-membered carbocyclic or heterocyclic ring comprising: carbon atoms and 0-2 heteroatoms selected from N, NR1 *-, O, and S(O)p, 0-1 carbonyl, and 0-3 double bonds, wherein said carbocyclic or heterocyclic ring is substituted with 0-2 Rb;
Ra is, independently at each occurrence, H, =0, F, OCF3, CF3, ORC, SRC, CN5 -NRl2Rl3, _c(0)Rc, -C(O)ORC, -C(O)NR12R13, -NR14C(O)Rd, -S(O)pNR'2R13,
-S(O)Rd, -S(O)2Rd, -(CH2)r-C3.io carbocycle substituted with 0-3 Re, or -(CH2)r-5- to 10-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NR/, O, and S(O)p, wherein said heterocycle is substituted with 0-3 Re;
Rb is, independently at each occurrence, H, =0, F, Cl, Br, I, -(CH2)rORc, SRc, CN, NO2, CF3, OCF3, -(CH2VNR12R13, -C(O)RC, ~(CH2)r-C(O)ORc, -(CH2VC(O)NR12Rl3, -NR^C(O)Rd, -S(O)pNR12R33, -S(O)Rd, -S(O)2Rd, Ci_4 haloalkyl, C1-4 haloalkyloxy-, Cj_4 alkyloxy-, C3-4 alkylthio-, C1.4 alkyl-C(O)-, CM alkyl-O-C(O)-, CM alkyl-C(O)NH-? C1-8 alkyl substituted with 0-2 Ra, C2.8 alkenyl substituted with 0-2 Ra, C2.g allcynyl substituted with 0-2 Ra, -(CH2VC3-Io carbocycle substituted with 0-3 Re, or -(CH2)r-5- to 10-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NRf O, and S(O)p, wherein said heterocycle is substituted with 0-3 Re;
Rc is, independently at each occurrence, H, -0P(0)(0Et)2, Cμg alkyl substituted with 0-2 Re. C2-S alkenyl substituted with 0-2 Re, C2_8 alkynyl substituted with 0-2 Re, -(CRfRr)r-C3-8 cycloalkyl substituted with 0-2 Re, -(CRfRf)r-C6-io aryl substituted with 0-2 Re, or -(CRfRf)r-5- to 10-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N5 NRf, O, and S(O)p, wherein said heterocycle is substituted with 0-2 Re;
Rd is, independently at each occurrence, CF3, OH, C1.4 alkoxy, Ci_6 alkyl, -(CH2)r-C3_io carbocycle substituted with 0-2 Re, or -(CH2VS- to 10- membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NRf, O5 and S(O)p, wherein said heterocycle is substituted with 0-2 Re;
Re is, independently at each occurrence, H, =0, -(CH2)r-0Rf, F, Cl, Br, I, CN, NO2, -(CH2VNR12R13, -C(O)Rf, -(CH2VC(O)ORf -NR14C(O)Rf -(CH2VC(O)NR12R13, -SO2NR12R13, -NRWSO2NR12R13, -NR14SO2-Ci-4 alkyl, -NRWSO2CF3, -NR14SO2-phenyl, -S(O)2CF3, -S(O)p-OR\ -(CF2)rCF3, Si(Me)3, Si(Me)2(^-Bu), Si(Ci-4 alkyl)3, Cχ_8 alkyl substituted with 0-2 Rg, C2-8 alkenyl substituted with 0-2 RS5 C2_8 alkynyl substituted with 0-2 RS, -(CH2)rC3.g cycloalkyl substituted with 0-2 RS, -(CH2)rC6-io aryl substituted with 0-2 R§, or
-(CH2)r-5- to 10-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NR/, O, and S(O)p, wherein said heterocycle is substituted with 0-2 RS;
Rf is, independently at each occurrence, H, Cμg alkyl, or -(CH2)n-phenyl; Rg is, independently at each occurrence, H, =0, ORf, F, Cl, Br, I, CN, NO2,
-NRfRf, -C(O)Rf -C(O)ORf, -NRfC(0)Rf, -C(O)NRfRf -SO2NRfRf -NRfSO2NRfRf -NRfSO2-Ci_4 alkyl, -NRfSO2CF3, -NRfSO2-phenyl, -S(O)2CF3, -S(0)P-CM alkyl, -S(O)p-phenyl, -(CF2)rCF3, C).6 alkyl, C2-6 alkenyl, or C2.6 alkynyl;
R*1 is, independently at each occurrence, C]_g alkyl substituted with 0-2 RS, -(CH2)trphenyl substituted with 0-2 RS, or -(CH2)n-5- to 10-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NRf O, and S(0)p, wherein said heterocycle is substituted with 0-2 R8;
R" is, independently at each occurrence, H, C]_$ alkyl substituted with 0-2 R§. -(CH2)n-phenyl substituted with 0-2 RS, or -(CH2)n-5- to 10-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NRf O, and S(O)p, wherein said heterocycle is substituted with 0-2 RS; n, at each occurrence, is selected from 0, 1, 2, 3, and 4; p, at each occurrence, is selected from 0, 1, and 2; r, at each occurrence, is selected from 0, 1, 2, 3, and 4; s, at each occurrence, is selected from 0, 1, 2, and 3; and t, at each occurrence, is selected from 1, 2, 3, and 4; provided that when ring D is dihydroindolyl, ring A is other than thiazolyl.
2. A compound according to Claim 1, wherein: W is O; and X2 is a bond, -CH2-, -CH2CH2-, -CH2CHMe-, -CH2CO-, or
ring D is substituted with 0-5 R6a and selected from:
wherein D1 is selected from: cyclopentyl, cylohexyl, piperidiii}4, tetrahydropyi"aiiyl, phenyl, pyridinyl, pyrimidinyl, thiophenyl, pyrrolyl, fuxanyl and thiazolyl;
W is O; and
X2 is a bond.
4. A compound according to Claim 1, wherein: ring A is substituted with 0-5 R1 and selected from: phenyl, pyridinyl, pyrimidinyl, furanyl, isoxazolyl, thiazolyl, thiadiazqlyl, benzothiazolyl, indolyl, and benziniidazolyl.
5. A compound according to Claim 1, wherein: ring A is substituted with 0-4 R1 and selected from: phenyl, pyridyl, isoxazolyl, furanyl, thienyl, thiazolyl, and benzothiazolyl; and ring B is substituted wititi 0-3 R7 and selected from:
6. A compound according to Claim 1, wherein: R1 is, independently at each occurrence, F, Cl, Br, I, CF3, -CF2CF3, OCF3,
-OCF2CF2H, -OCF2CF3, SiMe3, -(CRfRf)rORc, SRC, CN5 NO2, -(CRfRf)rNR12R13, -(CRfRf)rC(O)Rc, -(CRfRf)r-CO2Rc, -(CRfRf)r-C(O)NR12R13, -OP(O)(OEt)2, 4,4,5,5-tetramethyl-l,3,2-dioxaborolanyl, C1 _g alkyl substituted with 0-2 Ra, C2-8 alkenyl substituted with 0-2 Ra, C2-S alkynyl substituted with 0-2 Ra, -(CRfRf)1-C3.13 carbocycle substituted with 0-5 Rb, or -(CRfRf)r-5- to 10-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NR* 1, O, and S(O)p, wherein said heterocycle is substituted with 0-5 Rb; alternatively, two R1S on two adjacent carbon atoms are combined with the carbon atoms to which they attached, form a 5- to 7-membered carbocycle or • heterocycle comprising: carbon atoms and 0-3 additional heteroatoms selected from N, NR11 J O, and S(O)p, and 0-2 carbonyl groups, wherein said carbocycle or heterocycle is substituted with 0-4 Rb.
7. A compound according to Claim 1, wherein:
180
005/016525
R6a is, independently at each occurrence, F5 Cl, Br, I, -(CRiRVOR0, SRC, CN, CF3, OCF3, -CF2CF3, -OCF2CF2H, -OCF2CF3, -NR12R13, -C(O)Rc, -(CRfRf)rC(O)ORc, -Si(Me)3, CM haloalkyl, C] -4 haloalkyloxy-, C 1-4 alkyloxy-, CM alkylthio-, Ci-C4 alkyl-C(O)-, Cμ alkyl-O-C(O)-, CM alkyl-C(O)NH-, C1-8 alkyl substituted with 0-2 Ra 5 C2-8 alkenyl substituted with 0-2 Ra, C2-8 alkynyl substituted with 0-2 Ra, -(CRfRf)r-C3-1o carbocycle substituted with 0-2 Re, or -(CRfRf)1-S- to 10-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NR1 *, O, and S(O)p, wherein said heterocycle is substituted with 0-2 Re; and alternatively, when two R^a groups are attached to the same carbon atom or silicon atom, together with the carbon atom or silicon atom to which they are attached, they form a 3- to 7-membered carbocyclic or heterocyclic ring comprising: carbon atoms and 0-3 heteroatoms selected from N, NR1 ' , O, Si, and S(O)p, 0-1 carbonyl and 0-3 ring double bonds, wherein said carbocyclic or heterocyclic ring is substituted with 0-3 Rb; alternatively, when two R6a groups are attached to adjacent atoms, together with the atoms to which they are attached they form a 5- to 7-membered carbocyclic or heterocyclic ring comprising: carbon atoms and 0-2 heteroatoms selected from N, NR1 ] , O, Si, and S(O)p, 0-1 carbonyl and 0-3 ring double bonds, wherein said carbocyclic or heterocyclic ring is substituted with 0-3 Rb.
8. A compound according to Claim 1, wherein:
R11 is, independently at each occurrence, H, Cμg alkyl substituted with 0-2 Ra 5 -C(O)(CH2)n(C3.6 cycloalkyl), -C(O)(CH2)πphenyl, -C(O)O(C1-8 alkyl),
-C(O)O(CH2)n(C3.6 cycloalkyl), -C(O)O(CH2)nphenyl, -C(O)O(CH2)2-4(Ci-4 alkyl), -C(O)NH(CL6 alkyl), -S(O)2(C1-6 alkyl), -S(O)2(CH2)πphenyl, -(CRfRf)1-C3-7 cycloalkyl, -(CRfRf)r-phenyl, or -(CRfRf)1-S- to 6-membered heterocycle; wherein said alkyl, cycloaUcyl, phenyl, and aryl are substituted with 0-2 Rb, and said heteroaryl
181
and heterocycle are substituted with 0-2 Rb and comprise: carbon atoms and 1-4 heteroatoms selected from N, NR/, O, and S(O)p.
9. A compound according to Claim 1, wherein: ring A is substituted with 0-4 Rl and selected from: phenyl, pyridyl, isoxazolyl, fαranyl, thienyl, thiazolyl, and benzothiazolyl; ring B is substited with 0-3 R7 and selected from:
182
wherein D1 is selected from: cyclopentyl, cyiohexyl, piperidinyl, tetrahydropyranyl, phenyl, pyridinyl, pyrimidinyl, thiophenyl, pyrrolyl, furanyl and thiazolyl;
W is 0;
X2 is a bond; R1 is, independently at each occurrence, F, Cl, Br, I5 CF3, -CF2 CF3, OCF3,
-OCF2CF2H, -OCF2CF3, SiMe3, -(CRfRf)rORc, SRC, CN, NO2, -(CRfRf)rNR12R] 3, -(CRfRf)r-C(0)Rc, -(CRfRf)r-CO2Rc, -(CRfRf)r-C(O)NR12R13, -OP(O)(OEt)2, 4,4,5,5-tetramethyl-l,3,2-dioxaborolanyl, Cμ8 alkyl substituted with 0-2 Ra, C2-8 alkenyl substituted with 0-2 Ra, C2_s alkynyl substituted with 0-2 Ra, -(CRfRf)rC3.i3 carbocycle substituted with 0-5 Rb, or -(CRfRf)r-5- to 10-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N5 NR1 ', O5 and S(O)p, wherein said heterocycle is substituted with 0-5 BP; alternatively, two R1S on two adjacent carbon atoms are combined with the carbon atoms to which they attached, form a 5- to 7-membered carbocycle or heterocycle comprising: carbon atoms and 0-3 additional heteroatoms selected from N, NR1 1, O, and S(O)p, and 0-2 carbonyl groups, wherein said carbocycle or heterocycle is substituted with 0-4 Rb;
183
R6a is, independently at each occurrence, F, Cl, Br, I, -(CRiROrOR0, SRC, CN, CF3, OCF3, -CF2CF3, -OCF2CF2H5 -OCF2CF3, -NR12R13, -C(O)RC, -(CRfRf)rC(0)0Rc, -Si(Me)3, CM haloalkyl, C M haloalkyloxy-, C 1-4 alkyloxy-, C1.4 alkylthio-, Ci-C4 alkyl-C(O)-, CM alkyl-O-C(O)-, CM alkyl-C(O)NH-, C1-8 alkyl substituted with 0-2 Ra, C2-8 alkenyl substituted with 0-2 Ra, C2-8 alkynyl substituted with 0-2 Ra, -(CRfRf)rC3-io carbocycle substituted with 0-2 Re, or -(CRfRf)r-5- to 10-membered heterocycle comprising: carbon atoms and 1-4 heteroatorns selected from N, NR1 ' , O, and S(O)p, wherein said heterocycle is substituted with 0-2 Re; alternatively, when two R6a groups are attached to the same carbon atom or silicon atom, together with the carbon atom or silicon atom to which they are attached, they form a 3- to 7-membered carbocyclic or heterocyclic ring comprising: carbon atoms and 0-3 heteroatoms selected from N, NR1 3 , O, Si, and S(O)p, 0-1 carbonyl and 0-3 ring double bonds, wherein said carbocyclic or heterocyclic ring is substituted with 0-3 Rb; alternatively, when two R6a groups are attached to adjacent atoms, together with the atoms to which they are attached they form a 5- to 7-membered carbocyclic or heterocyclic ring comprising: carbon atoms and 0-2 heteroatoms selected from N, NR1 1 J O, Si, and S(O)p, 0-1 carbonyl and 0-3 ring double bonds, wherein said carbocyclic or heterocyclic ring is substituted with 0-3 Rb; and
R11 is, independently at each occurrence, H, Cμg alkyl substituted with 0-2 Ra, -C(θχCH2)n(C3-6 cycloalkyl), -C(O)(CH2)nphenyl, -C(O)O(CL8 alkyl), -C(O)O(CH2)n(C3-6 cycloalkyl), -C(O)O(CH2)nphenyl, -C(O)O(CH2)2^(CM alkyl), -C(O)NH(Ci^ alkyl), -S(O)2(CL6 alkyl), -S(O)2(CH2)nphenyl5 -(CRfRf)rC3-7 cycloalkyl, -(CRfRf)rphenyl, or -(CRfRf)1-S- to 6-membered heteroc3'cle; wherein said alkyl, cycloalkyl, phenyl, and aryl are substituted with 0-2 Rb, and said heteroaryl and heterocycle are substituted with 0-2 Rb and comprise: carbon atoms and 1-4 heteroatoms selected from N, NRf O, and S(O)p.
184
10. A compound according to claim 1, wherein the compound is of Formula (Ia):
(Ia) or a stereoisomer or pharmaceutically acceptable salt, or solvate thereof, wherein: ring A is
R1, Rla, R]b, and Rlc are, independently at each occurrence, H, F, Cl, Me, NH2, or OH;
R2, R2a, R2b, R2c5 R2d R35 R3a R3Cj R3d5 R4s R4a5 R4Cj R5? R5a? R5Cj ^d R5d are, independently at each occurrence, H, F, Cl, Br, I, CF3, -CF2CF3, OCF3, -OCF2CF2H, -OCF2CF3, SiMe3, -(CRfRf)r-ORc, SRC, CN, NO2, -(CRfRf)1-NR^RlS5
186
-(CRfRf)u-C(O)Rc, -(CRfRf)r-CO2Rc, -(CRfRf)11-C(O)NR12R13, -OP(O)(OEt)2, 4,4,5,5-tetramethyl-l,3,2-dioxaborolanyl, C1-8 alkyl substituted with 0-2 Ra, -(CRfRf)u-C3-6 carbocycle substituted with 0-2 Rb, or -(CRfRf)u-5- to 6-membered lieterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NR11, O, and S(O)p, wherein said heterocycle is substituted with 0-2 Rb; alternatively, Rl + R2, R2 + R3, R3 + R4, R4 + R5, Rla + R2a, R2a + R3a, R3a + R4a R4a + R5a Rlb + R2bs R2b + R5d Rl c + R3c5 R2c + R3c? R2d + R3d
R3c + R4c; or R4c + R5c; combine with the carbon atoms to which they are attached, form 5- tolO-membered carbocyclic or heterocyclic ring comprising: carbon atoms and 0-3 heteroatoms selected from N, NR1 *, O, and S(O)p, 0-1 carbonyl group, and additional 0-2 double bonds, wherein said carbocyclic or heterocyclic ring is substituted with 0-2 Rb;
R6a is, independently at each occurrence, F, Cl, Br, I, -(CRfRf)r-ORc, SRC, CN5 CF3, OCF3, -CF2CF3, -OCF2CF2H, -OCF2CF3, -NRl2R13, -C(O)RC, -(CRfRf)1-C(O)OR0, -Si(Me)3, Ci_4 haloalkyl, Ci_4 haloalkyloxy-, C1-4 alkyloxy-, CM alkylthio-, C1-C4 alkyl-C(O)-, C].4 alkyl-O-C(O)-, Ci_4 alkyl-C(O)NH-, Cμg alkyl substituted with 0-2 Ra, C2_8 alkenyl substituted with 0-2 Ra C2.g alkynyl substituted with 0-2 Ra, -(CRfRf)r-C3.io carbocycle substituted with 0-2 Re, or -(CRfRf)r-5- to 10-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NRl 1, O, and S(O)p, wherein said heterocycle is substituted with 0-2 Re; alternatively, when two R^a groups are attached to the same carbon atom or silicon atom, together with the carbon atom or silicon atom to which they are attached, they form a 3- to 7-membered carbocyclic or heterocyclic ring comprising: carbon atoms and 0-3 heteroatoms selected from N, NR11, O, Si, and S(O)p, 0-1 carbonyl and 0-3 ring double bonds, wherein said carbocyclic or heterocyclic ring is substituted with 0-3 Rb; alternatively, when two R^a groups are attached to adjacent atoms, together with the atoms to which they are attached they form a 5- to 7-membered carbocj'clic or heterocyclic ring comprising: carbon atoms and 0-2 heteroatoms selected from N,
187
NR1 1, O, Si, and S(0)p, 0-1 carbonyl and 0-3 ring double bonds, wherein said carbocyclic or heterocyclic ring is substituted with 0-3 Rb;
R7 is, independently at each occurrence, H, =0, F, Cl, Br, I, OCF3, CF3, ORC, SRc, CN, NO2, -NR12R13, -C(O)RC, -C(O)ORC, -C(O)NR12R13, -NR14C(0)Rd, -S(O)PNR12R13 , -S(O)Rd, -S(O)2Rd, C1-6 alkyl substituted with 0-2 Ra,
-(CH2)u-C3-io carbocycle substituted with 0-3 Rb, or -(CH2)u-5- to 10-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NR7b, O, and S(O)p, wherein said heterocycle is substituted with 0-3 Rb;
R7b is H, C1-4 alkyl, -C(O)(Ci_4 alkyl), -C(O)phenyl, -C(O)benzyl, or benzyl; R11 is, independently at each occurrence, H, Cμg alkyl substituted with 0-2
Ra, -C(O)(CH2)n(C3-6 cycloalkyl), -C(O)(CH2)πphenyl, -C(O)O(CL8 alkyl), -C(O)O(CH2)n(C3-6 cycloalkyl), -C(O)O(CH2)nphenyl, -C(O)O(CH2)2-4(Ci-4 alkyl), -C(O)NH(C1-6 alkyl), -S(O)2(Ci^ alkyl), -S(O)2(CH2)nphenyl, -(CRfRf)r-C3_7 cycloalkyL -(CRfRf)rphenyl, or -(CRfRf)r-5- to 6-membered heterocycle; wherein said alkyl, cycloalkyl, phenyl, and aryl are substituted with 0-2 Rb, and said heteroaryl and heterocycle are substituted with 0-2 Rb and comprise: carbon atoms and 1-4 heteroatoms selected from N, NRf, O, and S(O)p;
R12 is, independently at each occurrence, H, C 1-6 alkyl, -C(O)(C1-6 alkyl), -C(O)(CH2)nphenyl, -C(O)(CH2)n(5- to 6-membered heteroaryl), -C(O)O(C1-4 alkyl), -C(O)OCH2phenyl, -(CH2)nC(O)OCH2(5- to 6-membered heteroaryl), -(CH2)X1OC(O)(C1-4 alkyl), -(CH2)nOC(O)phenyl, -(CH2)nOC(O)(5- to 6-membered heteroaryl), -(CH2)nC(O)O(C1-4 alkyl), -(CH2)nC(O)Ophenyl, -(CH2)nC(O)O(5- to 6-membered heteroaryl), -(CH2)πC(O)NH(d.6 alkyl), -(CH2)nC(O)NHphenyL -(CH2)πC(O)NH(5- to 6-membered heteroaryl), -(CH2)tOC(O)NH(Ci-6 alkyl), -(CH2)tOC(O)NHphenyl, -(CH2)tOC(O)NH(5- to 6-membered heteroaryl), -S(O)2(C1-6 alkyl), -S(O)2(CH2)nphenyl, -S(O)2(CH2)n(5- to 6-membered heteroaryl),
or -(CRfRf)n- 5- to 6-membered heteroaryl; wherein said alkyl, and arjd are substituted with 0-2 RS; and said heteroaryl is substituted with
0-2 Rg and comprises: carbon atoms and 1-4 heteroatoms selected from N, NR11, O, and S(O)p;
R13 is, independently at each occurrence, H, Cμg alkyl, or -(CH2)n-phen}4; alternatively, R12 and R13, when attached to the same nitrogen, combine to form a 5- to 10-membered heterocyclic ring comprising: carbon atoms and 1-2 additional heteroatoms selected from N, NR11, O, and S(O)p;
R14 is, independently at each occurrence, H, Cμg alkyl substituted with 0-2 R14a, C2_6 alkenyl substituted with 0-2 R14a, Ci-β alkynyl substituted with 0-2 R14a, -(CH2)U-C3_6 cycloalkyl substituted with 0-3 RS, -(CH2)u-phenyl substituted with 0-3 Rg, or -(CH2)u-5- to 6-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NR1 *, O, and S(O)p, wherein said heterocycle is substituted with 0-3 Rg;
R14a is, independently at each occurrence, H, C1-4 alkyl, ORf, Cl, F, Br, I, =0, CF3, CN5 NO2, -C(O)Rf, -C(O)ORf -C(O)NR12R13, or -S(O)pRf; Ra is, independently at each occurrence, H3 =0, F, OCF3, CF3, ORC, SRC, CN,
-NR12R13, -C(O)RC, -C(O)ORC, -C(O)NR12R13, -NR14C(0)Rd, -S(O)pNR12R13, -S(O)Rd, -S(O)2Rd, -(CH2)u-C3_io carbocycie substituted with 0-3 Re, or -(CH2)u-5- to 10-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NRf, O, and S(O)p, wherein said heterocycle is substituted with 0-3 Re;
Rb is, independently at each occurrence, H, =0, F, Cl, Br, I, -(CH2)r-ORc, SRC, CN, NO2, CF3, OCF3, -(CH2)r-NR12R13, -C(O)R0, -(CH2)rC(O)ORc, -(CH2VC(O)NR12R13, -NR14C(O)Rd, -S(O)pNR12R13, -S(O)Rd, -S(O)2Rd Ci-4 haloalkyl, Ci_4 haloalkyloxy-, C1-4 alkyloxy-, Cχ_4 alkylthio-, Ci_4 alkyl-C(O)-, C 1.4 alkyl-O-C(O)-, C j .4 alkyl-C(O)NH-, C1-6 alkyl substituted with 0-2 Ra, C2-4 alkenyl substituted with 0-2 Ra, C2-4 alkynyl substituted with 0-2 Ra, -(CH2)u-C3_io carbocycie substituted with 0-3 Re, or -(CH2)u-5- to 10-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NRf, O, and S(O)p, wherein said heterocycle is substituted with 0-3 Re;
189
Rc is, independently at each occurrence, H, -0P(0)(0Et)2, Ci_8 alkyl substituted λvith 0-2 Re, C2-4 alkenyl substituted with 0-2 Re, C2-4 alkynyl substituted with 0-2 Re, -(CH2)u-C3-8 cycloalkyl substituted with 0-2 Re, -(CH2)u-C6-io ^Y1 substituted with 0-2 Re, or -(CH2)u-5- to 10-membered heterocycle comprising: carbon, atoms and 1-4 heteroatorns selected from N, NRf, O, and S(O)p, wherein said heterocycle is substituted with 0-2 Re;
Rd is, independently at each occurrence, CF3, OH5 C] .4 alkoxy, Cj.6 alkyl, -(CH2)u-C3-io carbocycle substituted with 0-2 Re, or -(CH2)u-5- to 10- membered heterocycle comprising: carbon atoms and 1-4 heteroatorns selected from N, NRf, O, and S(O)p, wherein said heterocycle is substituted with 0-2 Re;
Re is, independently at each occurrence, H, =0, -(CH2)r-0Rf, F, Cl, Br, I, CN, NO2, -(CH2)U-NR12R13, -C(O)Rf -(CH2)r-C(O)ORf, -NR14C(0)Rf, -(CH2VC(O)NR12RlS5 -SO2NRl2Rl3, -NRl4SO2NR12Rl3, -NRWSO2-C1-4 alkyl, -NRl4SO2CF3, -NR14SO2-ρhenyl, -S(O)2CF3, -S(O)p-Cμ4 alkyl, -S(O)p-phenyl, ~(CF2)UCF3, Ci_6 alkyl substituted with 0-2 RS, C2_4 alkenyl substituted with 0-2 Rg, C2-4 alkynyl substituted with 0-2 RS5 -(CH2)U-C3-S cycloalkyl substituted with 0-2 RS, -(CH2VC6-10 aryl substituted with 0-2 RS, or -(CH2)u-5- to 10-membered heterocycle comprising: carbon atoms and 1-4 heteroatorns selected from N, NRf, O, and S(O)p, Λvherein said heterocycle is substituted with 0-2 RS; Rf is, independently at each occurrence, H, or Cj-4 alkyl;
RS is, independently at each occurrence, H, =0, ORf, F, Cl, Br, I, CN, NO2, -NRfRf -C(O)Rf -C(O)ORf -NRfC(O)Rf, -C(O)NRfRf -SO2NRfRf, -NRfSO2NRfRf 5 -NRfSO2-Ci_4 alkyl, -NRfSO2CF3, -NRfSO2-phenyl, -S(O)2CF3, -S(0)p-Ci-4 alkyl, -S(O)p-phenyl, -(CF2)uCF3, Cχ_6 alkyl, C2-4 alkenyl, or C2.4 alkynyl; Rh is, independently at each occurrence, C^g alkyl substituted with 0-2 Rg, or
-(CH2)n-phenyl substituted with 0-2 Rg; n, at each occurrence, is selected from 0, 1, and 2; p, at each occurrence, is selected from O5 I5 and 2; r5 at each occurrence, is selected from O5 1, 2, 35 and 4;
190
s, at each occurrence, is selected from O, 1, 2, and 3; t, at each occurrence, is selected from 1 and 2; and u, at each occurrence, is selected from O, 1, and 2; provided that when ring D is dihydroindolyl, ring A is other than thiazolyl.
11. A compound according to claim 1, wherein the compound is of Formula (Ia):
(Ia) or a stereoisomer or pharmaceutically acceptable salt, or solvate thereof, wherein: ring A is
wherein the phenyl ring in each of the structures is substituted with 0-2 R6a;
R1, Rla, and Rlb ai-e, independently at each occurrence, H, F, Cl, Me, NH2,
. R2, R2b, R2c, and R2d are, independently at each occurrence, H, F, Cl, Br,
193
Ci-6 alkyl, Ci_6 aUcoxy, -O(CH2)8CO2Me, -O(CH2)2C(Me)2θMe3 -O(CH2)2OCOMe, NO2, CF3, CF2CF3, 2-CH2N(Me)2-Ph, Ph, cyclohexoxy, 4-Me-cyclohexoxy, cyclohexyhnethoxy, (1 -Bn-pyrrolidin-3-3'l)oxy, (1 -Bn-pyrrolidin-3-yl)methoxy, (1 H-pyrrol-1 -yl)ethoxy, (2-Bu-l H-irαidazol-4-yl)methoxy, (1 -Ph- IH-1, 2,3 -triazol-4-yl)methoxy, l-Bn-piperidin-3-oxy, l-Bn-piperidin-4-oxy, 4-Bn-morpholiii-2-yl-methoxy, benzoxy, 4-CO2Me-benzoxy or SiMe3;
R3, R3a 5 R3c, and R3d are, independently at each occurrence, H, F, Cl, Br, Ci_6 alkyl, Ci_6 alkoxy, -OCH(Me)CH2O-^-Bu, CF3, OCF3, -OCF2CF2H, -OCF2CF3, SiMe3, NH2, NMe2, -CH2NMe2, NEt2, -NHPh, -N(Me)Ph, -NH(4-0Me-Ph), -NH(2-CF3-Ph), -NH(2-f-Bu-Ph), -CH(Me)N(Me)(3-CF3-Bn), -CH(Me)N(Me)(4-CF3-Bn), -CH(Me)N(Me)(furan-2-ylmethyl),
-CH(Me)N(Me)(tliien-2-ylmethyl), -CH(Me)NHCH(Me)Ph, -CH(Me)OH, -CH(Me)O(Z-Pr)5 -CH(Me)O(Z-Bu), -CH(Me)O(3-CF3-Bn), -CH(Me)O(4-CF3-Bn),
-CH(Me)O(l-Bn-pyrrolidm-3-ylmethyl), -CH(Me)OCH2C(Me)2CH2NMe2, -CH(Me)OBn, -CH(Me)0(4-z-Pr-Bn), -CH(Me)0(4-0Ph-Bn),
-CH(Me)O(3,5-diCl-Bn), -CH(Me)OCH2(l-Bn-piperidin-4-yl), -CH2NHBn, -CH2NH(4-CF3-Bn), -CH2N(Me)Bn, -CH(Me)NHCH2-pyridin-2-yl, -CH(Me)NHCH2-p>τidin-4-yl, -CH(Me)NHCH2(6-Cl-pyridin-3-yl), -CH(Me)N(Me)(Z-Bu), -CH(Me)N(Me)Bn, -CH(Me)N(Me)(4-0Me-Bn), -CH(Me)N(Me)(4-F-Bn), -CH(Me)N(Me)(3-Cl-Bn), -CH(Me)N(Me)(4-Cl-Bn), -CH(Me)N(Me)(3,4-diCl-Bn), -CH(Me)N(Me)CH2CH2Ph, -CH(Me)N(Me)CH2-pyridin-2-yl, -CH(Me)N(Me)CH2-pyridin-3-yl, -CH(Me)N(Me)CH2-pyridin-4-yl, -CH(Me)N(Me)CH2-fui-an-2-yl, -CH(Me)N(Me)CH2-thien-2-yl, -CH(Me)N(Me)CH2-(5-Me-thien-2-yl), -CH(Me)N(Me)CH2-(5-Cl-thien-2-yl), -CH(Me)N(Et)Bn, -CH(Me)N(Et)(4-Me-Bn), -CH(Me)N(Et)(2-Cl-Bn), -CH(Me)N(Bn)CH2CN, -CH(Me)N(Bn)CH2CH2OH, -CH(Me)N(Bn)CH2CO2Me5 -CH(Me)N(Bn)CH2CONMe2, -CH(Me)N(Bn)CH2CON(Me)(Bn), -CH(Me)-isoindolin-2-yl, -CH(Me)-(1 ,2,3, 4-tetrah3^droisoquinolin-2-yl), -CH(Me)(4-Bn-piρerazin-l -yl), COMe, CO2Me, CO2Et, -CH2CO2Me5 -C(Me)2CO2Me, -O(CH2)5CO2Et5
194
-0(CH2)SCO2Me, -O(CH2)2C(Me)2OMe, -O(CH2)2OCOMe, -OCH2C(Me)2CH2NMe2, Ph, 2-CH2OH-Ph, 2-CH2N(Me)2-Ph, 3-CH2N(Me)2-Ph, 4-CH2N(Me)2-Ph, 2-((3-OH-pyrrolidin-l-yl)methyl)-Ph, phenoxy, 2-f-Bu-phenoxy, 2-CF3-phenoxy, Bn, benzoxy, 3-OMe-benzoxy, 4-CO2Me-benzoxy, 4-OCF3 -benzoxy, 2,4-diF-benzoxy, cyclohexyknethoxy, cyclohexylethoxy, cyclopentoxy, 3-Me-cycIopentoxy, cyclohexoxy, 4-Me-cyclohexoxy, 4-CO2Et-cyclohexoxy, l-Bn-pyrrolidin-3-oxy, (l-Bn-pyrrolidin-3-yl)methoxy, 1 H-pyrazol- 1 -yl, 3-CO2Et-5-Me- 1 H-pyrazol- 1 -yl, 4-CO2Et-5-Me- 1 H-pyrazol- 1 -yl, 5-Cθ2Et-3-Me-lH-ρyrazol-l-yl, (2-Bu-lH-iraidazol-4-yl)methoxy, lH-l,2,4-triazol-l-yl, (l-Ph-lHrl,2,3-triazol-4-yl)methoxy, 2-(lH-pyrrol-l-yl)ethoxy5 1 -piperidinyl, 1 -Bn-piperazin-4-yl, (2,2-diinethyl- 1 ,3-dioxolan~4-yl)methoxy, 1 -Bn-piperidin-3-oxy, 1 -Bn-piperidin-4-oxy, ( 1 -(z-Bu)-piperidin-4-yl)methoxy, (1 -isopentyl-piperidin-4-yl)methoxy, (1 -CO2(^-Bu)-piperidin-4-yl)methoxy, (1 -CO2Bn-piperidin-4-yl)methoxy, (1 -Bn-piperidin-4-yl)methoxy, (1 -phenethyl-piperidui-4-yl)methoxy, (1 -(4-phenylbutyl)~pipεridin-4-yl)methoxy, ( 1 -cyclohexylmetliyl-piperidin-4-yl-methoxy, (l-((pyridin-2-yl)methyl)-piperidin-4-yl)metlioxy, ( 1 -((pyridin-4-yl)metliyl)-piperidin-4-yl)methoxy, (1 -((153-dioxolan-2-yl)methyl)piperidin-4-yl)methoxy, N-morpholinyl, 4-Bn-morpholin-2-yl-methoxyJ C3-6 cycloalkyl substituted with -CO2Me, -CH2OH5 or -CH2OMe, 4,4,5,5-tetramethyl-l,3,2-dioxaboiOlanyl, or -OP(O)(OEt)2;
R4, R4a, aiαd R4c are H;
R5, R5a, R5c, and R5d are, independently at each occurrence, H, Me, F or Cl; alternatively, R1 + R2, R2 + R3, R3 + R4, R4 + R5, R3a + R4a, R4a + R5a,
Rib + R2b5 R2c + R3c5 R3c + R4c5 R4c + R5c} Rlb + R2b; R2d + R3d? or R2b + R5d; combine with the carbon atoms to which they attached, form 5- tolO-membered carbocyclic or heterocyclic ring comprising: carbon atoms and 0-3 heteroatoms selected from N, NR11, O, and S(0)p, 0-1 carbonyl group, and additional 0-2 double bonds, wherein said carbocyclic or heterocyclic ring is substituted with 0-2 Rb;
R6a is, independently at each occurrence, H, F, Cl, Br, I, CN, -C(Me)2CN,
195
C i_8 alkyl, C2-8 alkenyl, OH, SMe, S(Z-Pr), -C(Me)2OMe, -C(Me)2OEt, -C(Me)2OPr, -CHMeO(CH2)2OMe, -C(Me)2O(CH2)2OMe, -C(Et)2OMe, -C(Et)2OEt, COPh, -CH=CHCO2(^-Bu), CF3, OCF3, Ci-4 alkyloxy, CO2Me, -CH2CO2Me, C3_7 cycloalkyl, Ph, Bn, 1-pyrrolidinyl, 5-isoxazolyl, N-morpholinyl, 4-Bn-piperazinyl, 1-piperidinyl, l-Bn-piperidin-4-yl, Or -Si(Me)3; alternatively, when two R6a groups are attached to the same carbon atom, together with the carbon atom to which they are attached, they form a 3- to 7- membered carbocyclic or heterocyclic ring comprising: carbon atoms and 0-2 heteroatoms selected from N, NR1 ], O, and S(0)p, 0-1 carbonyl and 0-3 ring double bonds, wherein said carbocyclic or heterocyclic ring is substituted with 0-2 Rb; alternatively, when two R^a groups are attached to adjacent atoms, together with the atoms to which they are attached they form a 5- to 7-membered carbocyclic or heterocyclic ring comprising: carbon atoms and 0-2 heteroatoms selected from N, NR11, O, and S(O)p, 0-1 carbonyl and 0-3 ring double bonds, wherein said carbocyclic or heterocyclic ring is substituted with 0-2 Rb;
R7, R7a R7b, and R7d, independently at each occurrence, H, Me, Cl, Br, CN, OMe, SMe, or NHMe;
R8, R8a , R8b and R8e are, independently at each occurrence, H, Me, Cl, or CN;
R11 is, independently at each occurrence, Cμg alkyl, -CH2CH2OH, -CH2CH2OMe, -C(O)(C] -6 alkyl), -C(O)phenyl, -C(O)benzyl, -C(O)O(Ci-6 alkyl), -C(O)Obenzyl, -CH2CO2H, -CH2CO2(Ci-6 alkyl), -C(O)NH(Ci-6 alkyl), -C(O)NHbenzyl, -S(O)2(Ci_6 alkyl), -S(O)2phenyl, -S(O)2benzyl, phenyl, or benzyl;
Y is O, S, or NH;
Rb is, independently at each occurrence, H, F, Cl, Br, C] .4 alkyl, OH, CO2H, NH2, CF3, OCF3, Ci-4 alkyloxy, C3_7 cycloalkyl, phenyl, or benzyl;
Re is, independently at each occurrence, H, F, Cl, Cj .4 alkyl, OH, CO2H, NH2, CF3, OCF3, or CM alkyloxy; and p, at each occurrence, is selected from 0, 1, and 2; provided that when ring D is dihydroindolyl, ring A is other than thiazolyl.
196
Priority Applications (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL05779448T PL1750704T3 (en) | 2004-05-12 | 2005-05-11 | Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
| MXPA06013024A MXPA06013024A (en) | 2004-05-12 | 2005-05-11 | Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions. |
| DK05779448T DK1750704T3 (en) | 2004-05-12 | 2005-05-11 | Urea Antagonists of P2Y1 Receptors Useful in the Treatment of Thrombotic Conditions |
| JP2007513323A JP4795336B2 (en) | 2004-05-12 | 2005-05-11 | P2Y1 receptor urea antagonist useful for the treatment of thrombotic conditions |
| DE602005015577T DE602005015577D1 (en) | 2004-05-12 | 2005-05-11 | UML ANTAGONISTS OF THE P2Y1 RECEPTOR FOR THE TREATMENT OF THROMBOSELEIDES |
| CN2005800231306A CN1984655B (en) | 2004-05-12 | 2005-05-11 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| EP05779448A EP1750704B1 (en) | 2004-05-12 | 2005-05-11 | Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
| HR20090468T HRP20090468T1 (en) | 2004-05-12 | 2005-05-11 | Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
| CNA2005800236206A CN1984892A (en) | 2004-05-12 | 2005-05-11 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| AU2005245400A AU2005245400A1 (en) | 2004-05-12 | 2005-05-11 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| NO20065544A NO20065544L (en) | 2004-05-12 | 2006-12-01 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions. |
| CY20091101048T CY1109487T1 (en) | 2004-05-12 | 2009-10-13 | P2Y1 RECEPTOR UREA-TYPE ANTAGONISTS USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57028804P | 2004-05-12 | 2004-05-12 | |
| US60/570,288 | 2004-05-12 | ||
| US66573505P | 2005-03-28 | 2005-03-28 | |
| US60/665,735 | 2005-03-28 | ||
| US11/126,567 | 2005-05-10 | ||
| US11/126,567 US7550499B2 (en) | 2004-05-12 | 2005-05-10 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO2005113537A2 WO2005113537A2 (en) | 2005-12-01 |
| WO2005113537A3 WO2005113537A3 (en) | 2005-12-22 |
| WO2005113537B1 true WO2005113537B1 (en) | 2006-02-16 |
Family
ID=35169638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2005/016525 Ceased WO2005113537A2 (en) | 2004-05-12 | 2005-05-11 | Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7550499B2 (en) |
| EP (1) | EP1750704B1 (en) |
| JP (1) | JP4795336B2 (en) |
| KR (1) | KR20070011479A (en) |
| CN (2) | CN1984892A (en) |
| AU (1) | AU2005245400A1 (en) |
| CY (1) | CY1109487T1 (en) |
| DE (1) | DE602005015577D1 (en) |
| DK (1) | DK1750704T3 (en) |
| ES (1) | ES2328716T3 (en) |
| HR (1) | HRP20090468T1 (en) |
| MX (1) | MXPA06013024A (en) |
| NO (1) | NO20065544L (en) |
| PL (1) | PL1750704T3 (en) |
| PT (1) | PT1750704E (en) |
| SI (1) | SI1750704T1 (en) |
| WO (1) | WO2005113537A2 (en) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7470712B2 (en) * | 2004-01-21 | 2008-12-30 | Bristol-Myers Squibb Company | Amino-benzazoles as P2Y1 receptor inhibitors |
| AU2005245389A1 (en) | 2004-05-12 | 2005-12-01 | Bristol-Myers Squibb Company | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| US7645778B2 (en) | 2005-01-19 | 2010-01-12 | Bristol-Myers Squibb Company | Heteroaryl compounds as P2Y1 receptor inhibitors |
| DE602006021306D1 (en) | 2005-06-27 | 2011-05-26 | Bristol Myers Squibb Co | |
| ATE485269T1 (en) * | 2005-06-27 | 2010-11-15 | Bristol Myers Squibb Co | C-LINKED CYCLIC ANTAGONISTS OF THE P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC DISORDERS |
| WO2007002634A1 (en) * | 2005-06-27 | 2007-01-04 | Bristol-Myers Squibb Company | Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
| WO2007002584A1 (en) * | 2005-06-27 | 2007-01-04 | Bristol-Myers Squibb Company | Linear urea mimics antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
| WO2008023235A1 (en) * | 2006-08-25 | 2008-02-28 | Pfizer Products Inc. | Pyrazole derivatives as anti-platelet and anti-thrombotic agents |
| US7960569B2 (en) | 2006-10-17 | 2011-06-14 | Bristol-Myers Squibb Company | Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| KR100858460B1 (en) * | 2007-05-16 | 2008-09-12 | 최원진 | Preparation of Pickles |
| US8912184B1 (en) | 2010-03-01 | 2014-12-16 | Alzheimer's Institute Of America, Inc. | Therapeutic and diagnostic methods |
| NZ601788A (en) * | 2010-03-01 | 2014-11-28 | Myrexis Inc | Inhibitors of nicotinamide phosphoribosyltransferase and therapeutic uses thereof |
| EA201490152A1 (en) | 2011-06-24 | 2014-05-30 | Эмджен Инк. | TRPM8 ANTAGONISTS AND THEIR APPLICATION IN TREATMENT |
| JP2014517074A (en) | 2011-06-24 | 2014-07-17 | アムジエン・インコーポレーテツド | TRPM8 antagonists and their use in therapy |
| WO2013017678A1 (en) | 2011-08-04 | 2013-02-07 | Intervet International B.V. | Novel spiroindoline compounds |
| CN103172543B (en) * | 2011-12-21 | 2016-02-10 | 中国科学院上海药物研究所 | A kind of carbamide compounds, preparation method and its usage |
| WO2014022349A1 (en) * | 2012-08-01 | 2014-02-06 | Bristol-Myers Squibb Company | 7-hydroxy-spiropipiperidine indolinyl antagonists of p2y1 receptor |
| WO2014022343A1 (en) * | 2012-08-01 | 2014-02-06 | Bristol-Myers Squibb Company | 7-hydroxy-indolinyl antagonists of p2y1 receptor |
| EP2880034B1 (en) | 2012-08-01 | 2016-06-22 | Bristol-Myers Squibb Company | Amino-heteroaryl 7-hydroxy-spiropiperidine indolinyl antagonists of p2y1 receptor |
| US8952009B2 (en) | 2012-08-06 | 2015-02-10 | Amgen Inc. | Chroman derivatives as TRPM8 inhibitors |
| CN102924442B (en) * | 2012-11-15 | 2014-10-29 | 沈阳药科大学 | Chroman compound containing thiazole ring and analogue and medical applications thereof |
| CN103012381B (en) * | 2013-01-10 | 2015-01-07 | 山东大学 | Benzofuran compound, preparation method thereof and application of benzofuran compound in preparation of antiarrhythmic drugs |
| CN104402875A (en) * | 2014-12-25 | 2015-03-11 | 西安山川医药科技有限公司 | Synthesis method and application N-(2-aminoethyl)-N'-(6-substituted-2-benzothiazolyl)urea and salt compounds thereof |
| GB201721957D0 (en) * | 2017-12-27 | 2018-02-07 | Bp Oil Int | Methods for preparing fuel additives |
| GB201721964D0 (en) | 2017-12-27 | 2018-02-07 | Bp Oil Int | Methods for preparing fuel additives |
| GB201721960D0 (en) | 2017-12-27 | 2018-02-07 | Bp Oil Int | Methods for preparing fuel additives |
| GB201721961D0 (en) | 2017-12-27 | 2018-02-07 | Bp Oil Int | Methods for preparing fuel additives |
| GB201721967D0 (en) | 2017-12-27 | 2018-02-07 | Bp Oil Int | Methods for preparing fuel additives |
| CN110305141B (en) * | 2019-07-18 | 2022-01-11 | 深圳市三启药物开发有限公司 | Spiro (3, 3' -isopropyl pyrrole alkoxylated indole) liver X receptor regulator and preparation method and application thereof |
| CN114853684A (en) * | 2021-02-03 | 2022-08-05 | 北京万全德众医药生物技术有限公司 | Purification method of Lomepilon intermediate |
| EP4095134A1 (en) | 2021-05-25 | 2022-11-30 | UCL Business Ltd | Polycyclic compounds for the treatment of neurological indications |
| EP4094762A1 (en) | 2021-05-25 | 2022-11-30 | UCL Business Ltd | Treatment of neurological indications |
Family Cites Families (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3118888A (en) | 1964-01-21 | Acylated s-triazines and process for their preparation | ||
| NL280954A (en) | 1961-07-14 | |||
| US4179563A (en) | 1978-05-19 | 1979-12-18 | Warner-Lambert Company | 3-Aryloxy-substituted-aminopyridines and methods for their production |
| US4186199A (en) | 1978-11-02 | 1980-01-29 | American Hoechst Corporation | Indolo-,1,2-dihydroindolo-, and 1,2,6,7-tetrahydroindolo [1,7-ab][1,5] benzodiazepines |
| DE3065190D1 (en) | 1979-11-05 | 1983-11-10 | Beecham Group Plc | Enzyme derivatives, and their preparation |
| JPS56166180A (en) | 1980-05-28 | 1981-12-21 | Chugai Pharmaceut Co Ltd | Dibenzoxazepine derivative and its preparation |
| JPS56167649A (en) | 1980-05-30 | 1981-12-23 | Chugai Pharmaceut Co Ltd | Diphenyl ether derivative |
| JPS5872562A (en) * | 1981-10-23 | 1983-04-30 | Mitsubishi Chem Ind Ltd | Tetrahydrophtahlimides |
| US4663453A (en) | 1983-05-18 | 1987-05-05 | Hoechst-Roussel Pharmaceuticals Inc. | Benzo[b]pyrrolo[3,2,1-jk][1,4]benzodiazepines having dopamine receptor activity |
| US4761411A (en) | 1983-05-18 | 1988-08-02 | Hoechst-Roussel Pharmaceuticals Inc. | Dihydrobenzopyrrolobenzodiazepines useful for treating pyschoses |
| JPS62280847A (en) | 1986-05-30 | 1987-12-05 | Konica Corp | Silver halide photographic sensitive material containing new magnenta coupler |
| US4840947A (en) | 1986-10-14 | 1989-06-20 | Hoechst-Roussel Pharmaceuticals, Inc. | Antiinflammatory and analgesic piperidin-4-yl-tetracyclic benzodiazepines and use thereas |
| JP2577222B2 (en) | 1987-04-10 | 1997-01-29 | 興和株式会社 | New substituted anilide derivatives |
| JPH0339740A (en) | 1989-07-06 | 1991-02-20 | Konica Corp | Transfer type heatdevelopable color photosensitive material |
| JP2951434B2 (en) | 1991-04-18 | 1999-09-20 | 三菱製紙株式会社 | Electrophotographic photoreceptor |
| NZ264063A (en) | 1993-08-13 | 1995-11-27 | Nihon Nohyaku Co Ltd | N-(2-phenylpyrid-3-yl)- and n-(4-phenylpyrimidin-5-yl)-n'-phenylurea derivatives and pharmaceutical compositions |
| JP3395285B2 (en) | 1993-10-06 | 2003-04-07 | 日本製紙株式会社 | Thermal recording medium |
| US5547966A (en) | 1993-10-07 | 1996-08-20 | Bristol-Myers Squibb Company | Aryl urea and related compounds |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| DE4443641A1 (en) | 1994-12-08 | 1996-06-13 | Bayer Ag | Substituted carboxamides |
| EP0809492A4 (en) | 1995-02-17 | 2007-01-24 | Smithkline Beecham Corp | Il-8 receptor antagonists |
| PL322843A1 (en) | 1995-03-20 | 1998-02-16 | Lilly Co Eli | 5-substituted 3-91,2,3,6-tetrahydropyridin-4-yl)- and 3-9piperydin-4-4-yl0-1h-indoles nevel 5-htif natagonists |
| AU7340096A (en) | 1995-11-07 | 1997-05-29 | Kirin Beer Kabushiki Kaisha | Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same |
| CZ298098A3 (en) | 1996-03-25 | 1999-02-17 | Eli Lilly And Company | Tetrahydro-beta-carbolic compounds |
| CA2241687A1 (en) | 1996-10-30 | 1998-05-07 | Kenneth A. Jacobson | P2y receptor antagonists |
| US6020357A (en) | 1996-12-23 | 2000-02-01 | Dupont Pharmaceuticals Company | Nitrogen containing heteroaromatics as factor Xa inhibitors |
| US6187797B1 (en) | 1996-12-23 | 2001-02-13 | Dupont Pharmaceuticals Company | Phenyl-isoxazoles as factor XA Inhibitors |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| US5858289A (en) | 1997-02-24 | 1999-01-12 | Global Consulting, Inc. | Process for preparing compressed shape of ceramic fiber |
| ZA985247B (en) | 1997-06-19 | 1999-12-17 | Du Pont Merck Pharma | Guanidine mimics as factor Xa inhibitors. |
| AR016817A1 (en) * | 1997-08-14 | 2001-08-01 | Smithkline Beecham Plc | DERIVATIVES OF FENILUREA OR FENILTIOUREA, PROCEDURE FOR PREPARATION, COLLECTION OF COMPOUNDS, INTERMEDIARY COMPOUNDS, PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT AND USE OF SUCH COMPOUNDS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT |
| WO2000077027A2 (en) | 1999-06-14 | 2000-12-21 | Tularik Limited | Serine protease inhibitors |
| RU2212407C2 (en) | 1997-11-10 | 2003-09-20 | Бристол-Маерс Сквибб Компани | Benzothiazole inhibitors of protein tyrosine kinases |
| EP1047691A1 (en) | 1997-12-12 | 2000-11-02 | Smithkline Beecham Plc | Quinolinepiperazine and quinolinepiperidine derivatives, their preparation and their use as combined 5-ht1a, 5-ht1b and 5-ht1d receptor antagonists |
| DK1042305T3 (en) | 1997-12-22 | 2005-09-19 | Bayer Pharmaceuticals Corp | Inhibition of p38 kinase using symmetric and asymmetric diphenylureas |
| US7517880B2 (en) | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
| CA2318199A1 (en) * | 1998-01-15 | 1999-07-22 | Cor Therapeutics, Inc. | Platelet adp receptor inhibitors |
| US6329395B1 (en) | 1998-06-08 | 2001-12-11 | Schering Corporation | Neuropeptide Y5 receptor antagonists |
| DK1094816T3 (en) | 1998-07-06 | 2009-04-06 | Bristol Myers Squibb Co | Biphenylsulfonamides as dual angiotensin endothelin receptor antagonists |
| ATE287875T1 (en) | 1998-10-06 | 2005-02-15 | Dainippon Pharmaceutical Co | 2,3-DISUBSTITUTED PYRIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, ACTIVE INGREDIENT PREPARATIONS CONTAINING THEM AND INTERMEDIATE PRODUCTS FOR THE PRODUCTION |
| ATE290524T1 (en) | 1998-10-20 | 2005-03-15 | Takeda Pharmaceutical | AROMATIC AMINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MATERIALS CONTAINING SAME |
| GB9823873D0 (en) | 1998-10-30 | 1998-12-30 | Pharmacia & Upjohn Spa | 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents |
| HUP0202248A3 (en) | 1999-03-12 | 2006-06-28 | Boehringer Ingelheim Pharma | Compounds useful as anti-inflammatory agents |
| US6548529B1 (en) | 1999-04-05 | 2003-04-15 | Bristol-Myers Squibb Company | Heterocyclic containing biphenyl aP2 inhibitors and method |
| HUP0202708A3 (en) | 1999-04-15 | 2004-12-28 | Bristol Myers Squibb Co | Cyclic protein tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use |
| CO5200760A1 (en) | 1999-06-16 | 2002-09-27 | Smithkline Beecham Corp | RECEIVER ANTAGONISTS OF IL-8 CEPTOR IL-8 |
| JP2001089412A (en) | 1999-09-22 | 2001-04-03 | Otsuka Pharmaceut Co Ltd | Benzene derivative or its pharmaceutically acceptable salt |
| WO2001023358A1 (en) | 1999-09-27 | 2001-04-05 | Sagami Chemical Research Center | Pyrazole derivatives, intermediates for the preparation thereof, processes for the preparation of both and herbicides containing the derivatives as the active ingredient |
| MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
| DE19962924A1 (en) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituted oxazolidinones and their use |
| ATE336492T1 (en) | 2000-01-14 | 2006-09-15 | Us Gov Health & Human Serv | METHONOCARBACYCLOALKYLANALOGUES OF NUCLEOSIDES |
| WO2001055146A1 (en) | 2000-01-29 | 2001-08-02 | Lg Chem Investment Ltd. | FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF |
| US6906063B2 (en) | 2000-02-04 | 2005-06-14 | Portola Pharmaceuticals, Inc. | Platelet ADP receptor inhibitors |
| DE60114994T2 (en) * | 2000-02-04 | 2006-08-03 | Portola Pharmaceuticals, Inc., South San Francisco | PLATELET ADP RECEPTOR INHIBITORS |
| SK12712002A3 (en) | 2000-02-07 | 2003-02-04 | Abbott Gmbh & Co. Kg | 2-Benzothiazolyl urea derivatives and their use as protein kinase inhibitors |
| WO2001072751A1 (en) | 2000-03-29 | 2001-10-04 | Knoll Gesellschaft Mit Beschraenkter Haftung | Pyrrolopyrimidines as tyrosine kinase inhibitors |
| WO2001074793A2 (en) | 2000-04-03 | 2001-10-11 | 3-Dimensional Pharmaceuticals, Inc. | Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1 |
| AR035216A1 (en) | 2000-12-01 | 2004-05-05 | Astrazeneca Ab | MANDELIC ACID DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE DERIVATIVES, USE OF THESE DERIVATIVES FOR THE MANUFACTURE OF MEDICINES, TREATMENT METHODS, PROCESSES FOR THE PREPARATION OF THESE DERIVATIVES, AND INTERMEDIARY COMPOUNDS |
| JP2004517936A (en) | 2001-01-31 | 2004-06-17 | ピーアンドジー−クレイロール・インコーポレイテッド | A new coupler for use in oxidative hair dyeing |
| WO2002064211A1 (en) | 2001-02-09 | 2002-08-22 | Merck & Co., Inc. | Thrombin inhibitors |
| US6706711B2 (en) | 2001-04-27 | 2004-03-16 | Vertex Pharmaceuticals Incorporated | Pyrazole derived kinase inhibitor |
| IL158783A0 (en) | 2001-05-08 | 2004-05-12 | Schering Ag | Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 |
| AU2002317377A1 (en) | 2001-07-20 | 2003-03-03 | Cancer Research Technology Limited | Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer |
| JP2005501873A (en) | 2001-07-31 | 2005-01-20 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | Amine derivatives |
| WO2003013517A1 (en) | 2001-08-06 | 2003-02-20 | Pharmacia Italia S.P.A. | Aminoisoxazole derivatives active as kinase inhibitors |
| CN102617567A (en) | 2001-09-21 | 2012-08-01 | 百时美施贵宝公司 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors |
| WO2003045920A1 (en) | 2001-11-27 | 2003-06-05 | Merck & Co., Inc. | 4-aminoquinoline compounds |
| US20050154230A1 (en) | 2001-12-26 | 2005-07-14 | Bayer Healthcare Ag | Urea derivatives |
| JP2003192587A (en) | 2001-12-26 | 2003-07-09 | Bayer Ag | Urea derivative |
| AU2003210969A1 (en) | 2002-02-11 | 2003-09-04 | Bayer Corporation | Aryl ureas with raf kinase and angiogenesis inhibiting activity |
| AU2003209116A1 (en) | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Aryl ureas with angiogenesis inhibiting activity |
| AU2003209119A1 (en) | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
| DE10213228A1 (en) | 2002-03-25 | 2003-10-16 | Bayer Ag | Cyclopentene derivatives |
| CN1665808A (en) | 2002-05-06 | 2005-09-07 | 沃泰克斯药物股份有限公司 | Thiadiazoles or oxadiazoles and their use as inhibitors of JAK protein kinase |
| CA2488642C (en) | 2002-06-27 | 2011-09-06 | Dharma Rao Polisetti | Aryl carbonyl derivatives as glucokinase activators |
| US20060058395A1 (en) | 2002-08-01 | 2006-03-16 | Neurosearch A/S | Compounds useful for the treatment of diseases responsive to antiangiogenetic therapy |
| DE60328202D1 (en) | 2002-09-05 | 2009-08-13 | Neurosearch As | DIARYL HARVEST DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS |
| EP1402888A1 (en) | 2002-09-18 | 2004-03-31 | Jerini AG | The use of substituted carbocyclic compounds as rotamases inhibitors |
| US20040209930A1 (en) | 2002-10-02 | 2004-10-21 | Carboni Joan M. | Synergistic methods and compositions for treating cancer |
| EP1565429B1 (en) | 2002-11-21 | 2009-05-13 | Neurosearch A/S | Diaryl ureido derivatives and their medical use |
| US7056889B2 (en) | 2002-12-16 | 2006-06-06 | Kimberly-Clark, Worldwide, Inc. | Compounds that bind P2Y2 or P2Y1 receptors |
| WO2004085433A2 (en) | 2003-03-28 | 2004-10-07 | Pharmacia & Upjohn Company Llc | Positive allosteric modulators of the nicotinic acetylcholine receptor |
| US7247654B2 (en) | 2003-06-04 | 2007-07-24 | Bristol-Myers Squibb Company | 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors |
| TWM252710U (en) | 2003-07-18 | 2004-12-11 | Huei-Chiun Shiu | Annealing equipment |
| EP1661879A4 (en) | 2003-08-04 | 2006-11-29 | Ono Pharmaceutical Co | Diphenyl ether compound, process for producing the same, and use |
| AU2004266228A1 (en) | 2003-08-13 | 2005-03-03 | Amgen, Inc. | Melanin concentrating hormone receptor antagonists |
| CA2541751A1 (en) | 2003-10-14 | 2005-04-28 | Eli Lilly And Company | Phenoxyether derivatives as ppar modulators |
| PE20050444A1 (en) | 2003-10-31 | 2005-08-09 | Takeda Pharmaceutical | PYRIDINE COMPOUNDS AS PEPTIDASE INHIBITORS |
| ES2711313T3 (en) | 2003-12-26 | 2019-05-03 | Masatoshi Hagiwara | Method of regulating the phosphorylation of the SR protein and antiviral agents that comprise the regulator of the activity of the SR protein as an active ingredient |
| US7470712B2 (en) | 2004-01-21 | 2008-12-30 | Bristol-Myers Squibb Company | Amino-benzazoles as P2Y1 receptor inhibitors |
| TW200530236A (en) * | 2004-02-23 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Heteroaryl phenylurea |
| AU2005245389A1 (en) | 2004-05-12 | 2005-12-01 | Bristol-Myers Squibb Company | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| US7645778B2 (en) | 2005-01-19 | 2010-01-12 | Bristol-Myers Squibb Company | Heteroaryl compounds as P2Y1 receptor inhibitors |
| CA2598993C (en) | 2005-02-25 | 2013-09-03 | Serenex, Inc. | Tetrahydroindolone and tetrahydroindazolone derivatives |
| DE602006021306D1 (en) | 2005-06-27 | 2011-05-26 | Bristol Myers Squibb Co | |
| WO2007002584A1 (en) | 2005-06-27 | 2007-01-04 | Bristol-Myers Squibb Company | Linear urea mimics antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
| ATE485269T1 (en) | 2005-06-27 | 2010-11-15 | Bristol Myers Squibb Co | C-LINKED CYCLIC ANTAGONISTS OF THE P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC DISORDERS |
| WO2007002634A1 (en) | 2005-06-27 | 2007-01-04 | Bristol-Myers Squibb Company | Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
-
2005
- 2005-05-10 US US11/126,567 patent/US7550499B2/en active Active
- 2005-05-11 MX MXPA06013024A patent/MXPA06013024A/en active IP Right Grant
- 2005-05-11 KR KR1020067023615A patent/KR20070011479A/en not_active Ceased
- 2005-05-11 WO PCT/US2005/016525 patent/WO2005113537A2/en not_active Ceased
- 2005-05-11 DK DK05779448T patent/DK1750704T3/en active
- 2005-05-11 JP JP2007513323A patent/JP4795336B2/en not_active Expired - Fee Related
- 2005-05-11 CN CNA2005800236206A patent/CN1984892A/en active Pending
- 2005-05-11 PT PT05779448T patent/PT1750704E/en unknown
- 2005-05-11 SI SI200530770T patent/SI1750704T1/en unknown
- 2005-05-11 CN CN2005800231306A patent/CN1984655B/en not_active Expired - Fee Related
- 2005-05-11 ES ES05779448T patent/ES2328716T3/en not_active Expired - Lifetime
- 2005-05-11 DE DE602005015577T patent/DE602005015577D1/en not_active Expired - Lifetime
- 2005-05-11 EP EP05779448A patent/EP1750704B1/en not_active Expired - Lifetime
- 2005-05-11 PL PL05779448T patent/PL1750704T3/en unknown
- 2005-05-11 AU AU2005245400A patent/AU2005245400A1/en not_active Abandoned
- 2005-05-11 HR HR20090468T patent/HRP20090468T1/en unknown
-
2006
- 2006-12-01 NO NO20065544A patent/NO20065544L/en not_active Application Discontinuation
-
2009
- 2009-10-13 CY CY20091101048T patent/CY1109487T1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005113537B1 (en) | Urea antagonists of p2y1 receptor useful in the treatment of thrombotic conditions | |
| RU2399620C2 (en) | Quinuclidine derivatives and use thereof as m3 muscarinic receptor antagonists | |
| ES2858314T3 (en) | Procedure for antifungal compound | |
| JP2002030084A5 (en) | ||
| WO2007002635B1 (en) | C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions | |
| JP2002536329A5 (en) | ||
| JP2006524222A5 (en) | ||
| JP2009537461A5 (en) | ||
| JP2006505543A5 (en) | ||
| JP2005539088A5 (en) | ||
| JP2006504658A5 (en) | ||
| US8877787B2 (en) | EP4 agonist | |
| JP2005504042A5 (en) | ||
| WO2006078621B1 (en) | 2-phenoxy-n- (1, 3 , 4-thiadizol-2-yl) pyridin-3-amine derivatives and related compounds as p2y1 receptor inhibitors for the treatment of thromboembolic disorders | |
| AU2015231234A1 (en) | Antifungal compound process | |
| JP2007520440A5 (en) | ||
| JP2003502367A5 (en) | ||
| JP2008545718A5 (en) | ||
| JP2003507380A5 (en) | ||
| JP2007538031A5 (en) | ||
| KR100785675B1 (en) | Calcium receptor antagonist | |
| JP2009503110A5 (en) | ||
| RU2000101307A (en) | CHALKONS WITH ANTI-PROLIFERATIVE ACTIVITY | |
| TWI555744B (en) | Novel EP4 agonists | |
| WO1997049388A1 (en) | Remedies for renal diseases and organ-preserving agents |